Document is current

Article History

Received: 8 May 2024

Accepted: 23 January 2025

First Online: 1 February 2025

Declarations

:

: The study (including patient data collection) and the questionnaire represented observational, non-interventional, quality-improvement research with significant societal impact using anonymized data and no patient involvement. Thus, no specific legal approval or informed patient consent in accordance with Danish legislation was required.

: Not required, and not done, in accordance to national regulations.

: The authors did not receive payment related to the development of the manuscript. All authors received an honorarium from Boehringer Ingelheim with respect to this study for their role as Steering Committee members. ML: has received speaker and consultancy fees from AstraZeneca, Bayer, Boeringer Ingelheim, Novo Nordisk, GlaxoSmithKline, and is an investigator in clinical studies sponsored by Amgen, Bayer, Boehringer Ingelheim, Janssen, MSD and Novo Nordisk. STK: has received research grants from and lecture fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi and has served as a consultant for Bayer, Boehringer Ingelheim, MSD, Mundipharma, Novo Nordisk, and Sanofi. TS: none; MC: has received speaker/expert testimony honoraria from Novo Nordisk Denmark, Boehringer Ingelheim Denmark, and Abbott Rapid Diagnostics. RB: has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, and Boehringer Ingelheim, is an investigator in clinical studies sponsored by Boehringer Ingelheim, AstraZeneca, Bayer, and has received unrestricted research grants from Boehringer Ingelheim.